Levodropropizine

DB12472InvestigationalSmall molecule

Levodropropizine is a peripherally-acting antitussive agent. Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).

Formula / weight: C₁₃H₂₀N₂O₂ · 236.315 g/mol (avg)

Resolves to

Compound

UNII3O31P6T4G3CAS99291-25-5ChEMBLCHEMBL1288810ChEBI82722PubChem65859

Clinical / RWD

RxNorm52014ATCR05DB27

Structure

InChIKeyPTVWPYVOOKLBCG-ZDUSSCGKSA-NSMILES[H][C@@](O)(CO)CN1CCN(CC1)C1=CC=CC=C1

Targets

P0DOX4Immunoglobulin epsilon heavy chain

What you can answer from here — as of September 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

6ContraindicationsEach with its own population and attribute set

85Marketed productsAcross 6 countries and 43 labellers

1ATC codeIncluding every combination product, plus 6 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Levodropropizine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account